MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on June 27, 2006; DOI: 10.1124/mol.106.023549


0026-895X/06/7003-1132-1142$20.00
Mol Pharmacol 70:1132-1142, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.023549v1
70/3/1132    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mundell, S. J.
Right arrow Articles by Poole, A. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mundell, S. J.
Right arrow Articles by Poole, A. W.

Distinct Roles for Protein Kinase C Isoforms in Regulating Platelet Purinergic Receptor Function

Stuart J. Mundell, Matthew L. Jones, Adam R. Hardy, Johanna F. Barton, Stephanie M. Beaucourt, Pamela B. Conley, and Alastair W. Poole

Department of Pharmacology, School of Medical Sciences, University Walk, Bristol, United Kingdom (S.J.M., M.L.J., A.R.H., J.F.B., A.W.P.); Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, Bristol, United Kingdom (S.M.B.); and Portola Pharmaceuticals Inc., South San Francisco, California (P.B.C.)

ADP is a critical regulator of platelet activation, mediating its actions through two G protein-coupled receptors (GPCRs), P2Y1 and P2Y12. We have shown previously that the receptors are functionally desensitized, in a homologous manner, by distinct kinase-dependent mechanisms in which P2Y1 is regulated by protein kinase C (PKC) and P2Y12 by G protein-coupled receptor kinases. In this study, we addressed whether different PKC isoforms play different roles in regulating the trafficking and activity of these two GPCRs. Expression of PKC{alpha} and PKC{delta} dominant-negative mutants in 1321N1 cells revealed that both isoforms regulated P2Y1 receptor signaling and trafficking, although only PKC{delta} was capable of regulating P2Y12, in experiments in which PKC was directly activated by the phorbol ester phorbol 12-myristate 13-acetate (PMA). These results were paralleled in human platelets, in which PMA reduced subsequent ADP-induced P2Y1 and P2Y12 receptor signaling. PKC isoform-selective inhibitors revealed that novel, but not conventional, isoforms of PKC regulate P2Y12 function, whereas both novel and classic isoforms regulate P2Y1 activity. It is also noteworthy that we studied receptor internalization in platelets by a radioligand binding approach showing that both receptors internalize rapidly in these cells. ADP-induced P2Y1 receptor internalization is attenuated by PKC inhibitors, whereas that of the P2Y12 receptor is unaffected. Both P2Y1 and P2Y12 receptors can also undergo PMA-stimulated internalization, and here again, novel but not classic PKCs regulate P2Y12, whereas both novel and classic isoforms regulate P2Y1 internalization. This study therefore is the first to reveal distinct roles for PKC isoforms in the regulation of platelet P2Y receptor function and trafficking.


Received February 15, 2006; accepted June 27, 2006

Address correspondence to: Dr. Alastair W. Poole, Department of Pharmacology, School of Medical Sciences, University Walk, Bristol, BS8 1TD, UK. E-mail: a.poole{at}bris.ac.uk




This article has been cited by other articles:


Home page
BloodHome page
M. E. Daly, B. B. Dawood, W. A. Lester, I. R. Peake, F. Rodeghiero, A. C. Goodeve, M. Makris, J. T. Wilde, A. D. Mumford, S. P. Watson, et al.
Identification and characterization of a novel P2Y12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study
Blood, April 23, 2009; 113(17): 4110 - 4113.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Hoffmann, N. Ziegler, S. Reiner, C. Krasel, and M. J. Lohse
Agonist-selective, Receptor-specific Interaction of Human P2Y Receptors with {beta}-Arrestin-1 and -2
J. Biol. Chem., November 7, 2008; 283(45): 30933 - 30941.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. C. Y. Choi, J. Simon, K. W. K. Tsim, and E. A. Barnard
Constitutive and Agonist-induced Dimerizations of the P2Y1 Receptor: RELATIONSHIP TO INTERNALIZATION AND SCAFFOLDING
J. Biol. Chem., April 18, 2008; 283(16): 11050 - 11063.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. M. Urs, A. P. Kowalczyk, and H. Radhakrishna
Different Mechanisms Regulate Lysophosphatidic Acid (LPA)-dependent Versus Phorbol Ester-dependent Internalization of the LPA1 Receptor
J. Biol. Chem., February 29, 2008; 283(9): 5249 - 5257.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Hoffmeister, P. Riha, O. Neumuller, O. Danielewski, J. Schultess, and A. P. Smolenski
Cyclic Nucleotide-dependent Protein Kinases Inhibit Binding of 14-3-3 to the GTPase-activating Protein Rap1GAP2 in Platelets
J. Biol. Chem., January 25, 2008; 283(4): 2297 - 2306.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics